Hybrid imaging of the abdomen and pelvis.
Hybridbildgebung bei abdominellen Erkrankungen. Englische Version.
Cholangiocarcinoma
Liver
Positron emission tomography/magnetic resonance imaging
Rectum
Staging
Journal
Der Radiologe
ISSN: 1432-2102
Titre abrégé: Radiologe
Pays: Germany
ID NLM: 0401257
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
pubmed:
20
5
2020
medline:
26
1
2021
entrez:
20
5
2020
Statut:
ppublish
Résumé
Accurate imaging is crucial for lesion detection in abdominal organs, for the noninvasive characterization of focal and diffuse abnormalities, and for surgical planning. To accomplish these tasks, several imaging modalities such as multidetector computer tomography (MDCT), magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT) are used for abdominal imaging, providing important morphological, functional or metabolic information. More recently, PET/MRI has been gaining attention due to the possibility of combining high-resolution imaging with metabolic imaging. PET/MRI is a novel hybrid imaging technology that in the near future might play a pivotal role in the clinical management of oncologic and inflammatory abdominopelvic diseases. Despite the still limited number of published clinical studies, PET/MRI has been proven to be at least equivalent to PET/CT and to standalone MRI in a variety of oncologic disease. Moreover, in selected and focused clinical studies, it has been proven to outperform current standard of care imaging, for example, in evaluating cholangiocarcinomas, liver metastases, untreated and treated rectal cancer. This has also had an impact on therapeuticmanagement in some studies. Therefore in some institutions, including those of the authors, PET/MRI is becoming the new standard imaging modality in staging treatment-naïve intrahepatic massforming cholangiocarcinomas and prior to complicated hepatic surgery. Eine adäquate Bildgebung ist für die Detektion mitunter kleinster Läsionen, die noninvasive Charakterisierung von fokalen und diffusen Veränderungen, sowie die Planung chirurgischer Eingriffe von entscheidender Bedeutung. Zur Bewältigung dieser Aufgaben werden verschiedene bildgebende Verfahren wie die Multidetektor-Computertomographie (MDCT), Magnetresonanztomographie (MRT) und Positronen-Emissions-Tomographie/Computertomographie (PET/CT) eingesetzt, die wichtige morphologische, funktionelle oder metabolische Informationen liefern. In letzter Zeit gewinnt die PET/MRT aufgrund der Möglichkeit von Kombination hochauflösender Bildgebung und metabolischer Bildgebung zunehmend an Aufmerksamkeit. Die PET/MRT ist eine neuartige Hybridbildgebungstechnologie, die in naher Zukunft eine zentrale Rolle bei der klinischen Behandlung von onkologischen und entzündlichen Abdomen-Becken-Erkrankungen spielen könnte. Trotz der noch begrenzten Anzahl publizierter klinischer Studien hat sich die PET/MRT bei einer Vielzahl von onkologischen Erkrankungen als zumindest gleichwertig wie PET/CT und MRT als Einzeluntersuchung erwiesen. In ausgewählten und fokussierten klinischen Studien wurde zudem nachgewiesen, dass es die derzeitige Standardbildgebung beispielsweise in der Beurteilung von Cholangiokarzinomen, Lebermetastasen sowie unbehandelten und behandelten Rektumkarzinomen übertrifft. Dies hat sich in einigen Studien auch auf das therapeutische Management ausgewirkt. Daher ist die PET/MRT in einigen Institutionen zur neue Standardbildgebungsmethode, z. B. bei unbehandelten intrahepatischen Cholangiokarzinomen sowie vor komplizierten Leberoperationen geworden.
Autres résumés
Type: Publisher
(ger)
Eine adäquate Bildgebung ist für die Detektion mitunter kleinster Läsionen, die noninvasive Charakterisierung von fokalen und diffusen Veränderungen, sowie die Planung chirurgischer Eingriffe von entscheidender Bedeutung. Zur Bewältigung dieser Aufgaben werden verschiedene bildgebende Verfahren wie die Multidetektor-Computertomographie (MDCT), Magnetresonanztomographie (MRT) und Positronen-Emissions-Tomographie/Computertomographie (PET/CT) eingesetzt, die wichtige morphologische, funktionelle oder metabolische Informationen liefern. In letzter Zeit gewinnt die PET/MRT aufgrund der Möglichkeit von Kombination hochauflösender Bildgebung und metabolischer Bildgebung zunehmend an Aufmerksamkeit. Die PET/MRT ist eine neuartige Hybridbildgebungstechnologie, die in naher Zukunft eine zentrale Rolle bei der klinischen Behandlung von onkologischen und entzündlichen Abdomen-Becken-Erkrankungen spielen könnte. Trotz der noch begrenzten Anzahl publizierter klinischer Studien hat sich die PET/MRT bei einer Vielzahl von onkologischen Erkrankungen als zumindest gleichwertig wie PET/CT und MRT als Einzeluntersuchung erwiesen. In ausgewählten und fokussierten klinischen Studien wurde zudem nachgewiesen, dass es die derzeitige Standardbildgebung beispielsweise in der Beurteilung von Cholangiokarzinomen, Lebermetastasen sowie unbehandelten und behandelten Rektumkarzinomen übertrifft. Dies hat sich in einigen Studien auch auf das therapeutische Management ausgewirkt. Daher ist die PET/MRT in einigen Institutionen zur neue Standardbildgebungsmethode, z. B. bei unbehandelten intrahepatischen Cholangiokarzinomen sowie vor komplizierten Leberoperationen geworden.
Identifiants
pubmed: 32424463
doi: 10.1007/s00117-020-00661-x
pii: 10.1007/s00117-020-00661-x
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
80-89Références
Aklilu M, Eng C (2011) The current landscape of locally advanced rectal cancer. Nat Rev Clin Oncol 8(11):649–659
pubmed: 21826084
doi: 10.1038/nrclinonc.2011.118
pmcid: 21826084
Amorim BJ, Theodore SH, Blaszkowsky LS, Ferrone CR, Berger DL, Bordeianou LG, Ricciardi R et al (2019) Clinical impact of PET/MR in treated colorectal cancer patients. Eur J Nucl Med Mol Imaging 46(11):2260–2269
pubmed: 31359108
doi: 10.1007/s00259-019-04449-7
pmcid: 31359108
Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H, Bockisch A, Debatin JF, Freudenberg LS (2003) Non–small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229(2):526–533
pubmed: 14512512
doi: 10.1148/radiol.2292021598
pmcid: 14512512
Atkinson W, Catana C, Abramson JS, Arabasz G, McDermott S, Catalano O, Muse V et al (2016) Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients. Abdom Radiol 41(7):1338–1348
doi: 10.1007/s00261-016-0638-6
Beiderwellen K, Llanos G, Ruhlmann V, Heusch P, Gomez B, Nensa F, Umutlu L, Lauenstein TC (2015) Accuracy of [18F]FDG PET/MRI for the Detection of Liver Metastases. PLoS ONE. https://doi.org/10.1371/journal.pone.0137285
doi: 10.1371/journal.pone.0137285
pubmed: 26335246
pmcid: 4559465
Brendle C, Schwenzer NF, Rempp H, Schmidt H, Pfannenberg C, la Fougère C, Nikolaou K, Schraml C (2016) Assessment of metastatic colorectal cancer with hybrid imaging: comparison of reading performance using different combinations of anatomical and functional imaging techniques in PET/MRI and PET/CT in a short case series. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-015-3137-z
doi: 10.1007/s00259-015-3137-z
pubmed: 26224536
pmcid: 26224536
Brown G, Richards CJ, Bourne MW, Newcombe RG, Radcliffe AG, Dallimore NS, Geraint TW (2003) Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 227(2):371–377
pubmed: 12732695
doi: 10.1148/radiol.2272011747
pmcid: 12732695
Catalano OA, Coutinho AM, Sahani DV, Vangel MG, Gee MS, Hahn PF, Witzel T et al (2017) Colorectal cancer staging: comparison of whole-body PET/CT and PET/MR. Abdom Radiol 42(4):1141–1151
doi: 10.1007/s00261-016-0985-3
Catalano OA, Gee MS, Emanuele N, Selvaggi F, Pellino G, Cuocolo A, Luongo A et al (2016) Evaluation of quantitative PET/MR enterography biomarkers for discrimination of inflammatory strictures from fibrotic strictures in Crohn disease. Radiology 278(3):792–800
pubmed: 26436860
doi: 10.1148/radiol.2015150566
pmcid: 26436860
Catalano OA, Wu V, Mahmood U, Signore A, Vangel M, Soricelli A, Salvatore M, Gervais D, Rosen BR (2018) Diagnostic performance of PET/MR in the evaluation of active inflammation in Crohn disease. Am J Nuclear Med Mol Imaging 8(1):62–69
Catalano OA, Rosen BR, Sahani DV, Hahn PF, Guimaraes AR, Vangel MG, Nicolai E, Soricelli A, Salvatore M (2013) Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT: initial experience in 134 patients—a hypothesis-generating exploratory study. Radiology. https://doi.org/10.1148/radiology.13131306
doi: 10.1148/radiology.13131306
pubmed: 24009348
pmcid: 24009348
Catalano O, Kilcoyne A, Signore A, Mahmood U, Rosen B (2018) Lower gastrointestinal tract applications of PET/computed tomography and PET/MR imaging. Radiol Clin North Am 56(5):821–834
pubmed: 30119776
doi: 10.1016/j.rcl.2018.05.001
pmcid: 30119776
Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA (2006) Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13(10):1261–1268
pubmed: 16947009
doi: 10.1245/s10434-006-9023-y
pmcid: 16947009
Chen B‑B, Tien Y‑W, Chang M‑C, Cheng M‑F, Chang Y‑T, Wu C‑H, Chen X‑J et al (2016) PET/MRI in pancreatic and Periampullary cancer: correlating diffusion-weighted imaging, MR spectroscopy and glucose metabolic activity with clinical stage and prognosis. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-016-3356-y
doi: 10.1007/s00259-016-3356-y
pubmed: 27999896
pmcid: 7886184
Choi M, Kollepara SLS, Heilbrun LK, Smith D, Shields AF, Philip PA (2015) PET scans as a predictive marker of survival in advanced colorectal cancer. Clin Colorectal Cancer 14(1):35–40
pubmed: 25481195
doi: 10.1016/j.clcc.2014.10.001
pmcid: 25481195
Delso G, Fürst S, Jakoby B, Ladebeck R, Ganter C, Nekolla SG, Schwaiger M, Ziegler SI (2011) Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med 52(12):1914–1922
pubmed: 22080447
doi: 10.2967/jnumed.111.092726
pmcid: 22080447
Donati OF, Hany TF, Reiner CS, von Schulthess GK, Marincek B, Seifert B, Weishaupt D (2010) Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI. J Nucl Med. https://doi.org/10.2967/jnumed.109.068510
doi: 10.2967/jnumed.109.068510
pubmed: 20395324
pmcid: 20395324
Einspieler I, Thürmel K, Pyka T, Eiber M, Wolfram S, Moog P, Reeps C, Essler M (2015) Imaging large vessel vasculitis with fully integrated PET/MRI: a pilot study. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-015-3007-8
doi: 10.1007/s00259-015-3007-8
pubmed: 25876704
pmcid: 25876704
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247
doi: 10.1016/j.ejca.2008.10.026
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144(8):1941–1953
pubmed: 30350310
pmcid: 30350310
doi: 10.1002/ijc.31937
Ferrone C, Goyal L, Qadan M, Gervais D, Sahani DV, Zhu AX, Hong TS et al (2019) Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated Intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-019-04558-3
doi: 10.1007/s00259-019-04558-3
pubmed: 31705172
pmcid: 31705172
Fraum TJ, Fowler KJ, McConathy J, Dehdashti F (2016) Indeterminate findings on oncologic PET/CT: what difference does PET/MRI make? Nucl Med Mol Imaging. https://doi.org/10.1007/s13139-016-0405-1
doi: 10.1007/s13139-016-0405-1
pubmed: 27994684
pmcid: 5135691
de Geus-Oei L‑F, Vriens D, van Laarhoven HWM, van der Graaf WTA, Oyen WJG (2009) Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 43S–54S. https://doi.org/10.2967/jnumed.108.057224
Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R et al (2004) Cytoreductive surgery combined with perioperative Intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. https://doi.org/10.1200/jco.2004.10.012
doi: 10.1200/jco.2004.10.012
pubmed: 15310771
pmcid: 15310771
Heacock L, Weissbrot J, Raad R, Campbell N, Friedman KP, Ponzo F, Chandarana H (2015) PET/MRI for the evaluation of patients with lymphoma: initial observations. AJR Am J Roentgenol 204(4):842–848
pubmed: 25794075
pmcid: 4465553
doi: 10.2214/AJR.14.13181
Hectors SJ, Wagner M, Besa C, Huang W, Taouli B (2018) Multiparametric FDG-PET/MRI of hepatocellular carcinoma: initial experience. Contrast Media Mol Imaging. https://doi.org/10.1155/2018/5638283
doi: 10.1155/2018/5638283
pubmed: 30402045
pmcid: 6192124
Horvat N, Petkovska I, Gollub MJ (2018) MR imaging of rectal cancer. Radiol Clin North Am 56(5):751–774
pubmed: 30119772
doi: 10.1016/j.rcl.2018.04.004
pmcid: 30119772
Hu J, Chen F‑Y, Zhou K‑Q, Zhou C, Cao Ya, Hui-Chuan S, Fan J, Zhou J, Wang Z (2017) Intrahepatic cholangiocarcinoma patients without indications of lymph node metastasis not benefit from lymph node dissection. Oncotarget 8(69):113817–113827
pubmed: 29371948
pmcid: 5768365
doi: 10.18632/oncotarget.22852
Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte MF, Rigo P, Fillet G (2001) Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade Non-Hodgkin’s Lymphoma (NHL). Ann Oncol 12(6):825–830
pubmed: 11484959
doi: 10.1023/A:1011169332265
pmcid: 11484959
Joo I, Lee JM, Lee DH, Lee ES, Paeng JC, Lee JC, Jang J‑Y, Kim S‑W, Ryu JK, Lee K‑B (2017) Preoperative assessment of pancreatic cancer with FDG PET/MR imaging versus FDG PET/CT plus contrast-enhanced multidetector CT: a prospective preliminary study. Radiology. https://doi.org/10.1148/radiol.2016152798
doi: 10.1148/radiol.2016152798
pubmed: 28092495
pmcid: 28092495
Kang B, Jeong ML, Sub YS, Woo S, Hur BY, Jeon JH, Paeng JC (2016) Added value of integrated whole-body PET/MRI for evaluation of colorectal cancer: comparison with contrast-enhanced MDCT. Am J Roentgenol 206(1):W10–W20
doi: 10.2214/AJR.14.13818
Kawaoka T, Aikata H, Takaki S, Uka K, Azakami T, Saneto H, Jeong SC et al (2009) FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma. Hepatol Res 39(2):134–142
pubmed: 19208034
doi: 10.1111/j.1872-034X.2008.00416.x
pmcid: 19208034
Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ (2008) Functional imaging of neuroendocrine tumors with combined PET/CT using 68ga-DOTATATE (DOTA-DPhe1, Tyr3-Octreotate) and 18F-FDG. Cancer 112(11):2447–2455
pubmed: 18383518
doi: 10.1002/cncr.23469
pmcid: 18383518
Kelly H, Goldberg RM (2005) Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 23(20):4553–4560
pubmed: 16002847
doi: 10.1200/JCO.2005.17.749
pmcid: 16002847
van Kessel CS, Buckens CFM, van den Bosch MAAJ, van Leeuwen MS, van Hillegersberg R, Verkooijen HMV (2012) Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol 19(9):2805–2813
pubmed: 22396005
pmcid: 3433675
doi: 10.1245/s10434-012-2300-z
Kim JY, Myung-Hwan K, Tae YL, Hwang CY, Kim JS, Yun S‑C, Lee SS, Seo DW, Lee SK (2008) Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterology 103(5):1145–1151
doi: 10.1111/j.1572-0241.2007.01710.x
Kirchner J, Kirchner EM, Goltz JP, Lorenz V‑W, Kickuth R (2011) Prevalence of enlarged mediastinal lymph nodes in heavy smokers—a comparative study. Eur Radiol 21(8):1594–1599
pubmed: 21479857
doi: 10.1007/s00330-011-2111-9
pmcid: 21479857
Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348(25):2500–2507
pubmed: 12815135
doi: 10.1056/NEJMoa022136
pmcid: 12815135
Lee DH, Lee JM, Hur BY, Joo I, Yi N‑J, Suh K‑S, Kang KW, Han JK (2016) Colorectal cancer liver metastases: diagnostic performance and prognostic value of PET/MR imaging. Radiology 280(3):782–792
pubmed: 27092659
doi: 10.1148/radiol.2016151975
pmcid: 27092659
Leonard GD, Brenner B, Kemeny NE (2005) Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23(9):2038–2048
pubmed: 15774795
doi: 10.1200/JCO.2005.00.349
pmcid: 15774795
Li Y, Langhorst J, Koch AK, Demircioglu A, Nensa F, Kirchner J, Beiderwellen K et al (2019) Assessment of Ileocolonic inflammation in Crohn’s disease: which surrogate marker is better-maRIA, Clermont, or PET/MR index? Initial results of a feasibility trial. J Nucl Med 60(6):851–857
pubmed: 30389814
pmcid: 6581221
doi: 10.2967/jnumed.118.216937
Lötsch F, Waneck F, Auer H, Kaczirek K, Karanikas G, Ramharter M (2017) FDG-PET/MRI in alveolar Echinococcosis. Int J Infect Dis. https://doi.org/10.1016/j.ijid.2017.09.006
doi: 10.1016/j.ijid.2017.09.006
pubmed: 28935243
pmcid: 28935243
Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier A‑M (2006) Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244(2):254–259
pubmed: 16858188
pmcid: 1602156
doi: 10.1097/01.sla.0000217629.94941.cf
Mayerhoefer ME, Prosch H, Beer L, Tamandl D, Beyer T, Hoeller C, Berzaczy D et al (2019) PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-019-04452-y
doi: 10.1007/s00259-019-04452-y
pubmed: 31410538
pmcid: 6885019
Milojevic ITG, Milojevic B, Sobic-Saranovic DP, Artiko VM (2018) Impact of hybrid molecular imaging in Retroperitoneal fibrosis: a systematic review. Rheumatol Int. https://doi.org/10.1007/s00296-017-3798-y
doi: 10.1007/s00296-017-3798-y
pubmed: 28840309
pmcid: 28840309
Misra DP, Wakhlu A, Agarwal V, Danda D (2019) Recent advances in the management of takayasu arteritis. Int J Rheum Dis 22(Suppl 1):60–68
pubmed: 30698358
doi: 10.1111/1756-185X.13285
pmcid: 30698358
Mueller-Lisse UG, Mueller-Lisse UL, Meindl T, Coppenrath E, Degenhart C, Graser A, Scherr M, Reiser MF (2007) Staging of renal cell carcinoma. Eur Radiol 17(9):2268–2277
pubmed: 17318606
doi: 10.1007/s00330-006-0554-1
pmcid: 17318606
Nasu K, Kuroki Y, Nawano S, Kuroki S, Tsukamoto T, Yamamoto S, Motoori K, Ueda T (2006) Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 239(1):122–130
pubmed: 16493012
doi: 10.1148/radiol.2383041384
pmcid: 16493012
Ozawa Y, Hara M, Sakurai K, Nakagawa M, Tamaki T, Nishio M, Shibamoto Y (2010) Diagnostic accuracy of 18F-2-Deoxy-Fluoro-D-glucose positron emission tomography for pN2 lymph nodes in patients with lung cancer. Acta Radiol 51(2):150–155
pubmed: 20092375
doi: 10.3109/02841850903485763
pmcid: 20092375
Pace L, Emanuele N, Luongo A, Aiello M, Catalano OA, Soricelli A, Salvatore M (2014) Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-Deoxyglucose uptake in lesions and in normal organ tissues. Eur J Radiol. https://doi.org/10.1016/j.ejrad.2013.11.002
doi: 10.1016/j.ejrad.2013.11.002
pubmed: 24331845
pmcid: 24331845
Padhani AR, Koh D‑M, Collins DJ (2011) Whole-body diffusion-weighted MR imaging in cancer: current status and research direction. Radiology 261(3):700–718
pubmed: 22095994
doi: 10.1148/radiol.11110474
pmcid: 22095994
Park J‑W, Kim JH, Kim SK, Kang KW, Park KW, Choi J‑I, Lee WJ, Kim C‑M, Nam BH (2008) A Prospective Evaluation of 18F-FDG and 11C-Acetate PET/CT for Detection of Primary and Metastatic Hepatocellular Carcinoma. J Nucl Med 49(12):1912–1921
pubmed: 18997056
doi: 10.2967/jnumed.108.055087
pmcid: 18997056
Pellino G, Nicolai E, Catalano OA, Campione S, D’Armiento FP, Salvatore M, Cuocolo A, Selvaggi F (2016) PET/MR versus PET/CT imaging: impact on the clinical management of small-bowel Crohn’s disease. J Crohns Colitis 10(3):277–285
pubmed: 26574490
doi: 10.1093/ecco-jcc/jjv207
pmcid: 26574490
Plodeck V, Rahbari NN, Weitz J, Radosa CG, Laniado M, Hoffmann R‑T, Zöphel K et al (2019) FDG-PET/MRI in patients with pelvic recurrence of rectal cancer: first clinical experiences. Eur Radiol 29(1):422–428
pubmed: 29980927
doi: 10.1007/s00330-018-5589-6
pmcid: 29980927
Ponisio MR, McConathy J, Laforest R, Khanna G (2016) Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma. Pediatr Radiol 46(9):1258–1268
pubmed: 27003132
pmcid: 5841580
doi: 10.1007/s00247-016-3601-3
Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ (2018) Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15(2):95–111
pubmed: 28994423
doi: 10.1038/nrclinonc.2017.157
pmcid: 28994423
Ruhlmann V, Poeppel TD, Brandt AS, Grueneisen J, Ruhlmann M, Theysohn JM, Forsting M, Bockisch A, Umutlu L (2016) Erratum to: 18F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-016-3376-7
doi: 10.1007/s00259-016-3376-7
pubmed: 27000853
pmcid: 27000853
Ryan DP, Theodore SH, Bardeesy N (2014) Pancreatic adenocarcinoma. N Engl J Med 371:1039–1049. https://doi.org/10.1056/NEJMra1404198
Sailer AM, Bakers FC, Daemen JW, Vöö S (2018) 18F-FDG PET/MRI in the diagnosis of an infected aortic aneurysm. Cardiovasc Diagn Ther. https://doi.org/10.21037/cdt.2017.08.05
doi: 10.21037/cdt.2017.08.05
pubmed: 29850433
pmcid: 5949589
von Schulthess GK, Schlemmer H‑PW (2009) A look ahead: PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging 36(1):3–9
doi: 10.1007/s00259-008-0940-9
Sharma P, Kumar R, Singh H, Jeph S, Sharma DN, Bal C, Malhotra A (2012) Carcinoma endometrium: role of 18-FDG PET/CT for detection of suspected recurrence. Clin Nucl Med 37(7):649–655
pubmed: 22691505
doi: 10.1097/RLU.0b013e31824d24fa
pmcid: 22691505
Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30
pubmed: 28055103
doi: 10.3322/caac.21387
pmcid: 28055103
Slart RHJA1, Writing group, Reviewer group, Members of EANM Cardiovascular, Members of EANM Infection & Inflammation, Members of Committees et al (2018) FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET interest group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-018-3973-8
doi: 10.1007/s00259-018-3973-8
Son H, Khan SM, Rahaman J, Cameron KL, Prasad-Hayes M, Chuang L, Machac J, Heiba S, Kostakoglu L (2011) Role of FDG PET/CT in staging of recurrent ovarian cancer. Radiographics 31(2):569–583
pubmed: 21415197
doi: 10.1148/rg.312105713
pmcid: 21415197
Thuermel K, Einspieler I, Wolfram S, Moog P, Meier R, Schwaiger M, Heemann U (2017) Disease Activity and Vascular Involvement in Retroperitoneal Fibrosis: First Experience with Fully Integrated 18F-Fluorodeoxyglucose Positron Emission Tomography/magnetic Resonance Imaging Compared to Clinical and Laboratory Parameters. Clin Exp Rheumatol 35(Suppl 103 (1)):146–154
pubmed: 27974103
pmcid: 27974103
Torigian DA, Zaidi H, Kwee TC, Saboury B, Udupa JK, Cho Z‑H, Alavi A (2013) PET/MR imaging: technical aspects and potential clinical applications. Radiology 267(1):26–44
pubmed: 23525716
doi: 10.1148/radiol.13121038
pmcid: 23525716
Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, Tanaka A, Yamaoka Y, Yamamoto K, Konishi J (1995) In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36(10):1811–1817
pubmed: 7562048
pmcid: 7562048
Tsikitis VL, Larson DW, Huebner M, Lohse CM, Thompson PA (2014) Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer 14:336
pubmed: 24886281
pmcid: 4029910
doi: 10.1186/1471-2407-14-336
Vaglio A, Salvarani C, Buzio C (2006) Retroperitoneal fibrosis. Lancet. https://doi.org/10.1016/s0140-6736(06)68035-5
doi: 10.1016/s0140-6736(06)68035-5
pubmed: 16427494
pmcid: 16427494
Venook AP, Papandreou C, Furuse J, Ladrón de Guevara L (2010) The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. The Oncol 15(Suppl 4):5–13
doi: 10.1634/theoncologist.2010-S4-05
Wenter V, Sommer NN, Kooijman H, Maurus S, Treitl M, Czihal M, Dechant C, Unterrainer M, Albert NL, Treitl KM (2018) Clinical value of [18F] FDG-PET/CT and 3D-black-blood 3T-MRI for the diagnosis of large vessel vasculitis and single-organ vasculitis of the aorta. Q J Nucl Med Mol Imaging. https://doi.org/10.23736/S1824-4785.18.03036-4
Wilhelmsen M, Kring T, Jorgensen LN, Rørbæk Madsen M, Jess P, Bulut O, Nielsen KT, Lindbjerg Andersen C, Nielsen HJ (2014) Determinants of recurrence after intended curative resection for colorectal cancer. Scand J Gastroenterol 49(12):1399–1408
pubmed: 25370351
doi: 10.3109/00365521.2014.926981
pmcid: 25370351
Wudel LJ Jr, Delbeke D, Morris D, Rice M et al (2003) The role of [\^ sup 18\^ F] fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma/discussion. Am Surg 69(2):117
pubmed: 12641351
pmcid: 12641351